GHTC applauds G7 commitments to advancing innovation for emerging and enduring health threats
The Global Health Technologies Coalition (GHTC) welcomes commitments by G7 nations to advancing health research and development (R&D) included in the G7 Hiroshima Leaders’ Communiqué. R&D has long been the bedrock of progress in global health—from driving the near eradication of polio to dramatically extending the lives of those living with HIV/AIDS to changing the course of the COVID-19 pandemic. Yet sustained commitment is needed to deliver next generation innovations for enduring and emerging threats that are affordable and accessible to all people worldwide.
That is why we are pleased to see G7 leaders reiterate support for strengthening the R&D of medical countermeasures (MCMs)—in line with the 100 Days Mission to reduce the impact of future pandemics by developing MCMs within 100 days—and commit to enhancing equitable access to MCMs by supporting diversified manufacturing and the launch of a new MCM delivery partnership. We also welcome their acknowledgement of the need to increase contributions to the World Bank Pandemic Fund and advance a new surge financing framework for future pandemics, both of which are urgently needed to unlock resources to strengthen R&D capacities in low- and middle-income countries and advance a sustainable end-to-end MCM R&D ecosystem. Given the setbacks in global health caused by the COVID-19 pandemic and the rising threat of antimicrobial resistance, we are also encouraged to see leaders commit to spearheading research to tackle enduring challenges like HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases and implementing push and pull incentives to accelerate the R&D of antimicrobials.
While we applaud G7 leaders for this timely recognition of the critical role of R&D in driving global health progress and preventing pandemics, we now call on them to match this rhetoric with tangible policies and financial pledges to translate these commitments into reality.